Biosimilar Antibodies
Biosimilar Antibodies
Cost effective alternative to therapeutic antibodies!
Figure 1: ELISA plate precoated with 2 µg/ml Human CD47. Anti-CD47 (Magrolimab) biosimilar binds to Human CD47 and can be detected in a range of 0.061-1.606 ng/ml using a mFc-His tagged protein
What are Biosimilar Antibodies?
- A biosimilar antibody is a copy of a therapeutic antibody, with highly similar quality and efficacy, that has been approved for medical use.
- A therapeutic antibody is an antibody that is designed to recognise specific proteins on certain cells to iniate an immune response. Therapeutic antibodies are used to treat cancer, arthritis, Alzheimer's and other diseases.
- Research-grade biosimilar antibodies offer a more readily available and cost effective alternative to the original therapeutic antibody and can serve as a reference antibody in the development of new biologics.
Biosimilar Benefits
- Premium | Research grade (RUO) biosimilar antibodies
- Purified | Purified from cell supernatant by affinity chromatography
- Validated | Validated for target binding verification and off target effects by ELISA and flow cytometry to ensure quality and specificity
- Specific | Demonstrated to be low or non-immunogenic
- Cost | Cost effective alternative to therapeutic antibodies
Figure 2: HEK293 cells transfected with (A) human CD47 or (B) control protein. Cells were stained with 1 µg/ml anti-CD47 neutralising antibody (Magrolimab).
in vivo Functional Grade Biosimiliars
- Low Endotoxin | Our in vivo biosimiliars have the highest quality standards with low endotoxin levels and no detectable leachable protein A or aggregates
- High Purity | Purified by a multi-step process and are subjected to extensive QC to ensure high reproducibility between lots.
- Formulation | No preservatives, stabilisers or carrier protein. Sterile PBS free from K+ or Ca2+.
- Cost | Cost effective alternative to therapeutic antibodies
Popular Biosimiliar Antibodies
| BAFF Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Belimumab |
| Reactivity | Human |
| Application | ELISA |
| 4-1BB Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Utomilumab |
| Reactivity | Human |
| Application | ELISA |
| CD123 Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Talacotuzumab |
| Reactivity | Human |
| Application | ELISA, Flow Cytometry |
| CD38 Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Daratumumab |
| Reactivity | Human |
| Application | ELISA, Flow Cytometry |
| CTLA4 Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Ipilimumab |
| Reactivity | Human |
| Application | ELISA |
| IL6R Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Tocilizumab |
| Reactivity | Human |
| Application | ELISA, Flow Cytometry |
| Mesothelin Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Amatuximab |
| Reactivity | Human |
| Application | ELISA |
| PD-1 Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Pembrolizumab |
| Reactivity | Human |
| Application | ELISA, Flow Cytometry |
| PDL1 Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Atezolizumab |
| Reactivity | Human |
| Application | ELISA, Flow Cytometry |
| IL6 Biosimilar Antibody | |
|---|---|
| Therapuetic Antibody | Siltuximab |
| Reactivity | Human |
| Application | ELISA, Flow Cytometry |
Looking for a particular biosimilar? Use our LiveChat to get in touch and one of our specialists will be happy to help!
Biosimilar Applications
| Ligand binding assays | |
| Biologics development | |
| Reference antibody in pipeline drug development |
| In vivo Animal studies | |
| Reference antibody in ELISA and flow cytometry | |
| Studying of biochemical pathways |
Related Products
Biosimilar Technology
The Assay Genie biosimilar antibody range are produced using a revolutionary high throughput technology for monoclonal antibody development. Unlike hybridoma based monoclonal antibodies, this new technology can obtain IgG sequences from immunoreactive B cells directly with no need for hybridoma fusion. With no need for a hybridoma fusion, it will soon be possible to raise monoclonal antibodies from a range of animal species.
Over 1000 immunoreactive B cells can be isolated from a single animal. Such high numbers means greater success in obtaining monoclonal antibodies with higher specificity, sensitivity and affinity. Directly obtaining the IgG sequences also means direct editing and optimisation of antibodies is possible for humanization.
Get a Quote
If you would like a quote, or have a question, get in touch and one of our specialists will be happy to help!